The Worldwide Market for Anti-Infectives.pdf
《The Worldwide Market for Anti-Infectives.pdf》由会员分享,可在线阅读,更多相关《The Worldwide Market for Anti-Infectives.pdf(264页珍藏版)》请在三一文库上搜索。
1、Anti-Infectives October 2009 Kalorama Information A division of MarketR 38 East 29th Street Sixth Floor New York, New York 10016 212.807 .2660 t 800.298.5603 t 212.807 .2676 f Copyright 2009 Kalorama Information Reproduction without written permission, in any media now in existence or hereafter dev
2、eloped, in whole or in any part, is strictly prohibited ANTI-INFECTIVES: A GLOBAL MARKET OVERVIEW A KALORAMA INFORMATION MARKET INTELLIGENCE REPORT Anti-Infectives: A Global Market Overview has been prepared by Kalorama Information. We serve business and industrial clients in the United States and a
3、broad with a complete line of information services and research publications. Kalorama Information Market Intelligence Reports are specifically designed to aid the action-oriented executive by providing a thorough presentation of essential data and concise analysis. Author: Melissa Elder Publication
4、 Date: October 2009 38 East 29th Street New York, New York 10016 (800) 298-5699 Outside the U.S. (212) 807-2657 FAX: (212) 807-2676 www.KaloramaI E-MAIL: KLI2435380 The World Market for Anti Infectives ii Copyright 2009 Kalorama Information Reproduction without written permission, in any media now
5、in existence or hereafter developed, in whole or in any part, is strictly prohibited TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY1 Introduction.1 Scope and Methodology2 Total Size and Growth of the Market3 Issues and Trends Affecting Market6 Leading Competitors.7 CHAPTER TWO: INTRODUCTION AND IN
6、DUSTRY TRENDS.9 Overview.9 Introduction to Pathogens9 Demographics of the World11 Anti-Infective Drug Resistance.13 Antibiotic Abuse .14 Antibiotic Use in Agriculture15 Resistance in Select Populations.15 Children15 The Elderly.16 Compromised Individuals 16 Measures for Reducing Resistance17 Antibio
7、tic Cycling17 Antibiotic Education.17 Screening Hospitalized patients .17 HIV Trends 19 Infection Rates19 HIV and Women 20 Costs and Funding of HIV Treatment21 Access to HIV/AIDS Treatment.22 Manufacturer and Marketer Trends.24 Trends in Partnerships and Alliances24 Developers Trends.24 Trends in Rx
8、-to-OTC Switches.33 CHAPTER THREE: ANTIFUNGAL DRUGS.35 Overview.35 Types of Fungal Infections36 Superficial.36 The World Market for Anti Infectives iii Copyright 2009 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, in whole or
9、 in any part, is strictly prohibited. Systemic36 Histoplasmosis36 Coccidioidomycosis .37 Blastomycosis.38 Fungal Infection Statistics.38 Fungal Infection Risk42 Description of Antifungal Products .44 Systemic Antifungals44 Allylamines 44 Azoles.46 Polyene Macrolides49 Miscellaneous Antifungals.51 To
10、pical Antifungals.53 Allylamines 53 Azoles.56 Polyene Macrolides60 Miscellaneous Antifungals.61 Market Overview.63 Total Market Size and Forecast.63 Antifungal Market by Product Type .66 Allylamines 66 Azoles.66 Polyene Macrolides66 Other Antifungals.66 Antifungal Market by Geographical Region.71 Ma
11、rket Analysis by Treated Condition.74 Competitive Analysis.76 Leading Products.80 CHAPTER FOUR: ANTIBACTERIAL DRUGS.82 Overview.82 Classification of Antibacterial Organisms 82 Antimicrobial Spectrum86 Bacterial Resistance 86 Principles of Anti-bacterial Therapy.87 Infecting Organism.88 Antibiotic Se
12、nsitivity Testing.88 Site of Infection88 Host Defenses and Organ Function88 Antibiotic Pharmacokinetics 89 Monitoring Therapy .89 Combination Therapy and Prophylactic Use.89 Bacterial Infection Statistics90 Bacterial Infection Risk.94 Description of Antibacterial Products.97 Cephalosporins97 Macroli
13、des.107 The World Market for Anti Infectives iv Copyright 2009 Kalorama Information Reproduction without prior written permission, in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited. Penicillins.110 Quinolones 114 Sulfonamides120 Tetracyclines 122 C
14、arbopenems127 Systemic Miscellaneous Antibiotics.129 Market Overview.137 Total Market Size and Forecast.137 Antibacterial Market by Product Type141 Cephalosporins.141 Macrolides141 Penicillins.142 Quinolones .142 Sulfonamides142 Tetracyclines 143 Carbopenems143 Other Products144 Antibacterial Market
15、 by Geographical Region .148 Market Analysis by Treated Condition.151 Competitive Analysis.154 Leading Products.159 CHAPTER FIVE: ANTIVIRAL DRUGS.163 Overview: Introduction to Viruses 163 Examples of Pathogenic Viruses.163 Virus Function and Life History164 Replication in DNA Viruses .164 Replicatio
16、n of RNA Viruses .165 Replication in Retroviruses.165 Host Defenses Against Viruses .166 Viral Ploys to Invade Host Cells and Circumvent Host Responses 167 Invasion of Host Cells.167 Subversion of the Immune Response167 Avoidance of Immune Detection and Attack by Killer Cells168 HIV and AIDS168 Vira
17、l Infection Statistics170 Description of Antivirals Products.175 Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors175 Nucleoside Reverse Transcriptase Inhibitors.176 Combination Nucleoside Reverse Transcriptase Inhibitors .178 Nucleotide Analogue Reverse Transcriptase Inhibi
18、tors.179 Non-Nucleoside Reverse Transcriptase Inhibitors.180 Combination Non-Nucleoside Reverse Transcriptase Inhibitors.181 DNA Polymerase Inhibitors.182 Protease Inhibitors.183 The World Market for Anti Infectives v Copyright 2009 Kalorama Information Reproduction without prior written permission,
19、 in any media now in existence or hereafter developed, in whole or in any part, is strictly prohibited. Other Antivirals.186 Market Overview.189 Total Market Size and Forecast.189 Antiviral Market by Product Type193 Nucleoside Analogs193 Protease Inhibitors194 Other Antivirals194 Antiviral Market by
20、 Geographical Region199 Market Analysis by Treated Condition.202 Competitive Analysis.204 Leading Products.209 CHAPTER SIX: MARKET SUMMARY213 Total Market Size and Forecast.214 Market by Segment .217 CHAPTER SEVEN: CORPORATE PROFILES.219 Introduction.219 Abbott Laboratories221 AstraZeneca/MedImmune2
21、23 Bayer Schering Pharma AG.225 Bristol-Myers Squibb227 Daiichi Sankyo.229 Gilead Sciences.230 GlaxoSmithKline .232 Johnson poor quality of drugs available (most common in under developed regions); poor patient compliance and reduced course of treatment due to cost constraints. Drug resistance is be
22、coming more of an issue across the entire anti-infective continuum; however this is not a new concept. Resistances to antimicrobials were first recognized around 1950 starting with penicillin. Some of the most common resistant pathogens today include: Staphylococcus aureus Streptococcus Enterococcus
23、 Pseudomonas aeruginosa Clostridium difficile Salmonella and E. coli Acinetobacter baumannii Resistance is increasing and is concerning to the health industry because it is continuing to accelerate with more and more products being affected and the worlds tools for combating it decrease in power and
24、 number: Common deadly conditions showing resistance and forcing second and third-line therapy include respiratory infections, HIV/AIDS, diarrheal diseases, tuberculosis, and malaria. More than 90 percent of Staphylococcus aureus strains are resistant to penicillin and other related antibiotics; and
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- The Worldwide Market for Anti-Infectives Anti Infectives
链接地址:https://www.31doc.com/p-3800959.html